图S3。 图中所示的I mmunoblot的定量 1d。 Analysis of NOD1, p RIP2/ RIP2, pP65/P65 in Wt BMDM (n=6) and SMC (n=4) pre-treated with the NOD1 inhibitor Nodinitib-1 and/or stimulated with native LDL (as control for lipid load in the medium), oxLDL, c12-iE-DAP (an agonist for NOD1) and iE-Lys (an IE-DAP类似物分别无法激活NOD1)和C12-IE-DAP(NOD1的激动剂),分别为24h或48h。 蛋白水平归一化为微管蛋白。 数据表示为平均值±S.E.M. 独立实验的指示数(n)的。 *p <0.05,** p <0.01 vs.通过学生的t检验与LDL条件。 a.u.,任意单位。图S3。图中所示的I mmunoblot的定量1d。Analysis of NOD1, p RIP2/ RIP2, pP65/P65 in Wt BMDM (n=6) and SMC (n=4) pre-treated with the NOD1 inhibitor Nodinitib-1 and/or stimulated with native LDL (as control for lipid load in the medium), oxLDL, c12-iE-DAP (an agonist for NOD1) and iE-Lys (an IE-DAP类似物分别无法激活NOD1)和C12-IE-DAP(NOD1的激动剂),分别为24h或48h。蛋白水平归一化为微管蛋白。数据表示为平均值±S.E.M.。*p <0.05,** p <0.01 vs.通过学生的t检验与LDL条件。a.u.,任意单位。